Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has licensed VetDC for the development and commercialization of its investigational molecule, GS 9219, that is used in animal cancer.
Subscribe to our email newsletter
In a recent animal study where GS 9219’s intravenous version was examined for the treatment of canine lymphoma, GS 9219 demonstrated significant activity against spontaneous non-Hodgkin’s lymphoma in pet dog subjects and was well tolerated.
The results of the study suggested that GS 9219 could be an important new therapeutic option for animals suffering from lymphoma.
VetDC president and CEO Steven Roy said the transaction with Gilead is a major milestone in the ongoing efforts to license innovative products and intellectual properties that will advance veterinary medicine.